Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	11490
Country	United States

Received	2014-05-26 17:08
Peer-Review Started	2014-05-26 17:47
To Make the First Decision	2014-06-18 18:38
Return for Revision	2014-06-19 10:58
Revised	2014-07-01 23:34
Second Decision	2014-09-10 13:41
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-09-10 14:03
Articles in Press	2014-09-10 14:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-10-13 11:59
Publish the Manuscript Online	2014-10-20 09:08

ISSN	1948-5204 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Multimodality management of resectable gastric cancer: A review
Manuscript Source	Invited Manuscript
All Author List	Helen Shum and Lakshmi Rajdev
Funding Agency and Grant Number
Corresponding Author	Lakshmi Rajdev, MD, MS, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Road, 2nd Floor, Bronx, NY 10461, United States. lrajdev@montefiore.org
Key Words	Neoadjuvant chemotherapy; Adjuvant chemotherapy; Adjuvant chemoradiation; Gastric cancer; Gastric adenocarcinoma
Core Tip	Gastric adenocarcinoma is a difficult disease to treat. Surgical resection is the definitive therapy but recurrences are frequent. The use of a multidisciplinary approach to treatment decision-making is imperative. Surgical resection should be an R0 resection (with clear macroscopic and microscopic margins) and at least a D1 lymphadenectomy with a minimum of 15 lymph nodes sampled in the United States and a D2 lymphadenectomy elsewhere. Perioperative chemotherapy is a reasonable option based on the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. In patients who are evaluated after resection, adjuvant chemoradiation adds important survival benefit. Other options include adjuvant S-1 in Asian patients, capecitabine/oxaliplatin, and capecitabine/cisplatin.
Publish Date	2014-10-20 09:08
Citation	Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol 2014; 6(10): 393-402
URL	http://www.wjgnet.com/1948-5204/full/v6/i10/393.htm
DOI	http://dx.doi.org/10.4251/wjgo.v6.i10.393

Full Article (PDF)	WJGO-6-393.pdf
Full Article (Word)	WJGO-6-393.doc
Manuscript File	11490-Review.docx
Answering Reviewers	11490-Answering reviewers.pdf
Copyright License Agreement	11490-Copyright assignment.pdf
Peer-review Report	11490-Peer review(s).pdf
Scientific Misconduct Check	11490-CrossCheck.jpg
Scientific Editor Work List	11490-Scientific editor work list.pdf